0001209191-22-025537.txt : 20220425 0001209191-22-025537.hdr.sgml : 20220425 20220425171304 ACCESSION NUMBER: 0001209191-22-025537 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220421 FILED AS OF DATE: 20220425 DATE AS OF CHANGE: 20220425 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walker Neal CENTRAL INDEX KEY: 0001604457 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 22850592 MAIL ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-21 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001604457 Walker Neal C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 1 1 0 0 President and CEO Common Stock 2022-04-21 4 S 0 25000 15.2379 D 1290763 D Common Stock 2022-04-22 4 S 0 25000 15.0439 D 1265763 D Common Stock 2022-04-25 4 S 0 20000 15.1828 D 1245763 D These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Mark Ballantyne, Attorney-in-Fact 2022-04-25